Summary:
In individuals with alcohol use disorder (AUD), treatment with the GLP-1 receptor agonist exenatide did not significantly impact pro-inflammatory and metabolic biomarkers compared to a placebo group, and it was not associated with any notable adverse side effects.
| PICO | Description |
|---|---|
| Population | Individuals diagnosed with alcohol use disorder (AUD). |
| Intervention | Treatment with the GLP-1 receptor agonist exenatide. |
| Comparison | Placebo group receiving no active treatment. |
| Outcome | No significant effect of exenatide on pro-inflammatory and metabolic biomarkers compared to placebo. No notable adverse side effects were observed. |
Source: Hviid, Malthe E B, et al. “Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.” Read article here.
